GlobeNewswire Inc.T3·1mo ago
QCLS Q/C Technologies, Inc.
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
QCLS
—
—
What changed
Recent filings, trades and moves- Nov 18 Reports earnings
Key stats
Related
About
- Industry (SIC)
- IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES (2835) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 2
- List Date
- 2021-04-19
- CIK
- 0001321834
- Next Earnings
- 2026-11-18
- Headquarters
- New York, NY
- Homepage
- https://www.qctechnologies.com
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '25 | '26 | Avg |
|---|---|---|---|
| Jan | -- | -0.95% | -0.95% |
| Feb | -- | -6.28% | -6.28% |
| Mar | -- | -8.00% | -8.00% |
| Apr | -- | 10.29% | 10.29% |
| May | -- | 17.16% | 17.16% |
| Jun | -- | -7.14% | -7.14% |
| Jul | -- | -35.07% | -35.07% |
| Aug | -- | -15.64% | -15.64% |
| Sep | -11.70% | -59.28% | -35.49% |
| Oct | -5.95% | -43.89% | -24.92% |
| Nov | 6.23% | -11.93%* | -2.85% |
| Dec | 18.05% | -- | 18.05% |
| Total | 4.14% | -88.71% | -42.28% |
* Only 2 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.46
SMA 50: $0.84
SMA 200: $2.95
Current: $0.37
EMA 12: $0.42
EMA 26: $0.57
MACD: -0.1471 | Signal: 0.0243
BEARISH
ADX (14): 10.75
RANGE
+DI: 22.97
−DI: 30.65
Momentum Oscillators
RSI (14): 28.53
OVERSOLD
Stoch %K: 13.03
Stoch %D: 7.97
Williams %R: -78.27
Volume & Volatility
BB Upper: $0.59
BB Lower: $0.33
NEUTRAL
OBV: 374,843,514
Vol SMA 20: 177,009
Vol ROC: 112.00%
ATR: $0.08
True Range: $0.05
HV 20: 93.2%
HV 30: 90.7%
HV 60: 302.4%
Data Summary
Data Points: 283
Last Updated:
Date Range: 2025-09-25T00:00:00 – 2026-11-09T00:00:00
AI Analysis
LLM Stock Analysis Report: QCLS
Executive Summary
Overall Assessment: BEARISH (confidence level 6/10)
Key Drivers:
- Technical indicators suggest a bearish trend, with MACD indicating a potential sell signal
- Volatility is high, with beta at 2.57 and average true range at $0.34
Primary Risks:
- Downtrend momentum, potentially driven by negative news sentiment or regulatory issues
- High volatility, increasing the risk of sudden price movements
Recent News Sentiment Impact: N/A (no recent news available)
Technical Analysis
Trend Direction: Short-term: BEARISH (1-4 weeks) Medium-term: BEARISH (1-3 months) Long-term: NEUTRAL (3-12 months)
Support/Resistance Levels:
- SMA 20: $3.99
- Lower Bollinger Band: $3.49
Momentum Signals:
- RSI interpretation: NEUTRAL (51.86), suggesting a lack of momentum
- MACD signal: BEARISH crossover, indicating potential sell signal
- Bollinger Bands position: MEAN REVERSION (price touching lower band)
Volume Analysis:
- Volume SMA 20: 427967.58
- On-Balance Volume (OBV): 140618391.99
- Volume Rate of Change: -9.30%, suggesting a decline in trading activity
News & Sentiment Analysis
Recent Headlines Summary: N/A (no recent news available)
Sentiment Assessment: NEUTRAL (no recent news sentiment data available)
Catalyst Identification: None available
Market Narrative: No narrative can be established without recent news headlines or catalysts
Risk & Volatility Assessment
Beta Interpretation: HIGH RISK (beta 2.57, higher than market average)
Volatility Regime: HIGH VOLATILITY (historical volatility HV20 89.2%, HV30 117.4%)
Options Market Signals:
- IV Premium vs HV30: N/A (no data available), indicating a lack of options activity
Downside Protection:
- Support levels: SMA 20 ($3.99), Lower Bollinger Band ($3.49)
Market Context & Positioning
Sector Performance: N/A (no sector performance data available)
Institutional Activity: None available
Correlation Analysis: N/A (no correlation data available)
Relative Valuation: No valuation data available
Key Levels & Action Items
Critical Price Levels:
- SMA 20: $3.99
- Lower Bollinger Band: $3.49
Breakout/Breakdown Levels: N/A (no technical levels available)
Time-Sensitive Catalysts: None available
Risk Management:
- Stop-loss levels: below SMA 20 ($3.92) or Lower Bollinger Band ($3.49)
- Position sizing considerations: consider scaling down positions due to high volatility and bearish trend
Generated
News
All QCLS news →
QCLS Options Activity & IV Rank
Loading options activity...
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 2.1576
Alpha: -79.18%
Correlation: 0.1599
R-Squared: 2.6%
Stock Volatility: 185.5%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
QCLS Institutional Ownership (13F)
Filings for 2026-06-30 · 7 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
QCLS Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Joshua Silverman | Executive Chairman | Award (A) | +94,010 | — | EDGAR | |
| 2026-10-02 | Joshua Silverman | Executive Chairman | Award (A) | +16,806 | — | EDGAR | |
| 2026-05-14 | Chelsea Sierra Voss | Director | Buy (P) | +1,753 | $3.15 | $5.5K | EDGAR |
| 2026-04-15 | Bruce Bernstein | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-04-15 | Mitchell Glass | Chief Medical Officer | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-04-15 | Billy Joe White | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-04-15 | Joshua Silverman | Executive Chairman | Award (A) | +162,162 | — | EDGAR | |
| 2026-04-15 | Stephen Friscia | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-04-15 | Chelsea Sierra Voss | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-01-30 | Chelsea Sierra Voss | Director | Award (A) | +237,500 | — | EDGAR | |
| 2025-11-18 | PharmaCyte Biotech, Inc. | 10%+ Owner | Buy (P) | +1,779,730 RSU | — | EDGAR | |
| 2025-11-17 | Billy Joe White | Director | Award (A) | +22,839 | — | EDGAR | |
| 2025-11-17 | Mitchell Glass | Director, Chief Medical Off. | Award (A) | +11,420 | — | EDGAR | |
| 2025-11-14 | Gary M Rauch | Award (A) | +11,420 | — | EDGAR | ||
| 2025-11-14 | Joshua Silverman | Executive Chairman | Award (A) | +91,356 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
QCLS Insider Holdings
7 insiders · @ $0.37
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Chelsea Sierra Voss | Director | 301,455 | $111.5K | $5.5K | 3 | 2026-05-14 |
| 2 | Joshua Silverman | Executive Chairman | 116,835 | $43.2K | $0 | 5 | 2026-10-02 |
| 3 | Billy Joe White | Director | 25,024 | $9.3K | $0 | 3 | 2026-04-15 |
| 4 | Bruce Bernstein | Director | 25,000 | $9.2K | $0 | 2 | 2026-04-15 |
| 5 | Stephen Friscia | Director | 25,000 | $9.2K | $0 | 3 | 2026-04-15 |
| 6 | Gary M Rauch | 12,500 | $4.6K | $0 | 2 | 2025-11-14 | |
| 7 | Mitchell Glass | Chief Medical Officer | 12,500 | $4.6K | $0 | 3 | 2026-04-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
QCLS Board & Officers
As of SEC filings through Oct 2, 2026Directors 6
- Billy Joe White · since Aug 7, 2017
- Joshua Silverman · since Sep 6, 2018
- Mitchell Glass · since Apr 8, 2024
- Stephen Friscia · since Jun 13, 2024
- Bruce Bernstein · since Sep 1, 2025
- Chelsea Sierra Voss · since Jan 16, 2026
Officers 4
- Charles Todd Fagan · Chief Financial Officer · since Aug 11, 2026
- Mitchell Glass · Director, Chief Medical Off. · listed since Oct 2025
- Yossef Ehrlichman · Chief Technology Officer · since Sep 14, 2026
- Joshua Silverman · Executive Chairman · listed since Oct 2025
10% owners 1
- PharmaCyte Biotech, Inc. (entity) · since May 23, 2024
Changes in the last 10 years (33)
| Sep 14, 2026 | Yossef Ehrlichman became Chief Technology Officer |
| Aug 11, 2026 | Charles Todd Fagan became Chief Financial Officer |
| Jan 16, 2026 | Chelsea Sierra Voss became a director |
| Oct 6, 2025 | Mitchell Glass listed as Director, Chief Medical Off. (previously President, CMO) in SEC filings |
| Oct 6, 2025 | Joshua Silverman first listed as Executive Chairman in an SEC filing |
| Sep 1, 2025 | Bruce Bernstein became a director |
| Apr 18, 2025 | Mitchell Glass first listed as President, CMO in an SEC filing |
| Apr 18, 2025 | Gary M Rauch no longer listed as VP - Finance, Treasurer in SEC filings |
| Jun 13, 2024 | Stephen Friscia became a director |
| May 23, 2024 | PharmaCyte Biotech, Inc. became a 10% owner |
| Apr 15, 2024 | The company announced the departure of Adam Kaplin as Chief Scientific Officer in an SEC filing |
| Apr 8, 2024 | Mitchell Glass became a director |
| Jun 9, 2023 | Paul Rivard listed as Chief Legal Officer (previously EVP of Operations, GC) in SEC filings |
| Apr 21, 2021 | Christopher C Schreiber no longer listed as Executive Chairman in SEC filings |
| Apr 16, 2021 | Paul Rivard became EVP of Operations, GC |
| Apr 16, 2021 | Jude Uzonwanne became a director |
| Apr 16, 2021 | Craig Eagle became a director |
| Apr 16, 2021 | Christopher C Chapman JR became a director |
| Apr 16, 2021 | Christopher C Chapman JR became President, Chief Med. Officer |
| Apr 16, 2021 | Caroline C Williams became a 10% owner |
| Apr 16, 2021 | Adam Kaplin became Chief Scientific Officer |
| Feb 1, 2021 | Ian Rhodes became Interim CFO |
| Aug 19, 2020 | Stuart M Benson became Chief Financial Officer |
| Jan 3, 2020 | Christopher C Schreiber first listed as Executive Chairman in an SEC filing |
| Dec 6, 2019 | Sander Gerber became a 10% owner |
| Dec 6, 2019 | Hudson Bay Capital Management LP became a 10% owner |
| Nov 1, 2019 | Robert C Schroeder became a director |
| Oct 5, 2018 | Howard Yeaton became CEO, CFO |
| Sep 6, 2018 | Joshua Silverman became a director |
| Oct 24, 2017 | John J Gormally first listed as a director in an SEC filing |
| Aug 7, 2017 | Richard C Tarbox III became a director |
| Aug 7, 2017 | Christopher C Schreiber became a director |
| Aug 7, 2017 | Billy Joe White became a director |
Not reported recently (15)
- Ian Rhodes · Last reported as Interim CFO in an SEC filing dated Apr 18, 2025
- Christopher C Schreiber · Last reported as a director in an SEC filing dated Mar 25, 2025
- Jude Uzonwanne · Last reported as a director in an SEC filing dated Mar 25, 2025
- Craig Eagle · Last reported as a director in an SEC filing dated Nov 25, 2024
- Paul Rivard · Last reported as Chief Legal Officer in an SEC filing dated Aug 24, 2023
- Christopher C Chapman JR · Last reported as a director in an SEC filing dated Jun 30, 2023
- Caroline C Williams · Last reported as a 10% owner in an SEC filing dated Apr 26, 2021
- Robert C Schroeder · Last reported as a director in an SEC filing dated Apr 20, 2021
- Stuart M Benson · Last reported as Chief Financial Officer in an SEC filing dated Aug 31, 2020
- Sander Gerber · Last reported as a 10% owner in an SEC filing dated Mar 3, 2020
- Hudson Bay Capital Management LP · Last reported as a 10% owner in an SEC filing dated Mar 3, 2020
- Howard Yeaton · Last reported as CEO, CFO in an SEC filing dated Oct 3, 2019
- John J Gormally · Last reported as Chief Executive Officer in an SEC filing dated Apr 10, 2018
- Richard C Tarbox III · Last reported as a director in an SEC filing dated Apr 10, 2018
- Brandon Thomas Knox · Last reported as a director in an SEC filing dated Feb 13, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-09-18
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-12 | 0001493152-26-037333 | EDGAR |
ETF Holders
1 ETF hold QCLS
1 shown · $89.14K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $89,143 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
QCLS vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| IDXX Idexx Laboratories Inc | $53.3B | 47.7 | +11.9% | +5.5% | 24 |
| LNTH Lantheus Holdings, Inc | $6.6B | 24.5 | +2.3% | +50.2% | 4 |
| NEOG Neogen Corp | $2.6B | — | −0.3% | +72.6% | 10 |
| CLDX Celldex Therapeutics, Inc | $2.3B | — | −93.9% | +15.7% | 9 |
| NTLA Intellia Therapeutics, Inc | $1.6B | — | +45.0% | +31.5% | 55 |
| QDEL QuidelOrtho Corporation Common Stock | $734M | — | −4.5% | −58.0% | 54 |
| ACHV Achieve Life Sciences, Inc. | $693M | — | — | +36.4% | 47 |
| MYGN Myriad Genetics Inc | $564M | — | −3.2% | −6.5% | 39 |
| QCLS Q/C Technologies, Inc. Common Stock | $3M | — | — | −91.3% | — |
| Peer median | $2.0B | 36.1 | −0.3% | +23.6% | 32 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.